Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized comparative study of Zostavax shingles vaccine in adults ≥50 years
2009-012458-19Phase 3Completed
- Sponsor
- Sanofi Pasteur MSD S.N.C.
- Start
- Jul 2009
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoster vaccine, live in herpes zoster (HZ) and postherpetic neuralgia (PHN), sponsored by Sanofi Pasteur MSD S.N.C. Primary endpoints: Co-primary immunogenicity endpoints and Clinical prevention of herpes zoster and post-herpetic neuralgia. Started Jul 2009; status: completed.
02
Drugs
zoster vaccine, live
03
Conditions
herpes zoster (HZ)postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on 2009-012458-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012458-19.